PHARMA SIGNALOPEN RESEARCH PLATFORM →
CLINICAL TRIAL PROFILE · UPDATED 2026-09-29

Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer

NCT07189455 · Phase 3 · Recruiting

PHASEPhase 3
STATUSRecruiting
ENROLLMENT420
EST. COMPLETION2028-10

Conditions

Small-cell Lung Cancer

Interventions

ZG006Topotecan

Study details

SPONSORSuzhou Zelgen Biopharmaceuticals Co.,Ltd
START DATE2025-12-12

Related company profiles

Zelgen Biopharmaceuticals

688266.SS

Primary source

Trial status and dates can change. Confirm enrollment and eligibility against the linked ClinicalTrials.gov record.

Evidence & limits

Source: Open the source record

Record identifier
NCT07189455
Event / action date
Not separately retained
Source update date
Not separately retained
Platform retrieval / processing date
Not separately retained

What it supports. Study information reported by the sponsor or investigator, including status, phase, enrollment, and recorded dates.

Limits. Registration or completion does not establish clinical success or approval. Sponsor-name associations can be ambiguous. Dates may be estimated; verify the live study record.

Connection basis. Company sponsor aliases and normalized lead-sponsor containment; the NCT identifier identifies the study.

What this record means · Report an issue with this record